作为动脉样硬化的潜在治疗剂的Cordyceps
1School of Marxism, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan Province, China.
Journal of integrative medicine
|March 17, 2024
概括
传统中医药中的科尔迪塞普斯 (Cordyceps) 通过减少炎症和胆固醇,在治疗动脉样硬化方面表现有前途. 本综述探讨了它的机制和新药开发的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
- 心血管研究研究心血管研究
背景情况:
- 动脉样硬化是全球主要的健康问题,推动了寻找新型治疗策略的研究.
- 传统的中医药,比如Cordyceps,正在越来越多地研究它们在治疗复杂疾病方面的潜力.
- 现有的研究突出显示了Cordyceps与动脉样硬化相关的多种药理活动.
研究的目的:
- 审查Cordyceps和Ophiocordyceps spp.的化学组成和药理作用. 体. 体. 这是一种体.
- 阐明Cordyceps抗动脉样硬化作用背后的机制.
- 为了澄清围绕科尔迪塞普斯和Ophiocordyceps sinensis在研究中的命名问题.
主要方法:
- 关于 Cordyceps 和动脉样硬化的研究的文献综述.
- 对药理作用的分析,包括抗炎,抗氧化,降胆固醇和抗血小板作用.
- 检查对血管内皮细胞中亡和自的作用.
主要成果:
- 科迪塞普斯表现出显著的抗炎和抗氧化特性,对动脉样硬化有益.
- 它有效降低胆固醇水平,并抑制血小板聚合.
- 科尔迪塞普斯调节了亡和自,这是血管健康的关键过程.
结论:
- 科尔迪塞普斯和Ophiocordyceps spp. 的种类. 菌具有显著的抗动脉样硬化潜力.
- 了解它的机制可以指导新药剂的开发.
- 澄清术语对于推动该领域的研究至关重要.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.1K
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.3K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
509
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
509
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164